TM4SF1-AS1: A Potential Drug Target and Biomarker (G100874091)

Target Name: TM4SF1-AS1

NCBI ID: G100874091

TM4SF1-AS1

Other Name(s): TM4SF1 antisense RNA 1, transcript variant 1 | TM4SF1-AS1 variant 1 | TM4SF1 antisense RNA 1

TM4SF1-AS1: A Potential Drug Target and Biomarker

TM4SF1-AS1, also known as heat shock protein 1 (Hsp1), is a protein that plays a crucial role in the regulation of cellular stress response. It is a heat shock protein that is expressed in a variety of tissues, including muscle, heart, brain, and liver, and its levels increase significantly in response to increased temperatures, such as those caused by exercise or stress.

TM4SF1-AS1 functions as a molecular chaperone, helping to transport and protect damaged or misfolded proteins from the endoplasmic reticulum (ER) to the cytosol for recycling or degradation. It also interacts with other proteins involved in the stress response pathway, including Hsp70 and Hsp90, to modulate their activity and influence the cellular stress response.

Recent studies have identified TM4SF1-AS1 as a potential drug target due to its involvement in a variety of cellular processes that are related to human disease, including cancer, neurodegenerative diseases, and autoimmune disorders. The high level of expression of TM4SF1-AS1 in various tissues and the evidence of its involvement in cellular stress response make it an attractive target for small molecule inhibitors.

One of the key advantages of TM4SF1-AS1 as a drug target is its expression in a variety of human tissues, including the brain, which is home to many of the body's most important neural and cognitive functions. This means that any drug that targets TM4SF1-AS1 is likely to have a more widespread and beneficial impact on human health. Additionally, the fact that TM4SF1-AS1 is involved in the regulation of cellular stress response suggests that it may be a good candidate for targeting drugs that are designed to modulate the cellular stress response in ways that are beneficial.

Another potential advantage of TM4SF1-AS1 as a drug target is its role in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the buildup of neurofibrillary tangles, which are thought to be the hallmark of these diseases. TM4SF1-AS1 has been shown to be involved in the regulation of neurofibrillary tangles and has been identified as a potential therapeutic target for neurodegenerative diseases.

In addition to its potential role in neurodegenerative diseases, TM4SF1-AS1 is also involved in the development and progression of cancer. The high level of expression of TM4SF1-AS1 has been observed in a variety of cancer types, including breast, ovarian, and colorectal cancers. Additionally, TM4SF1-AS1 has been shown to play a role in the regulation of cell cycle progression and the maintenance of cancer cell survival, which suggests that it may be a good candidate for targeting drugs that are designed to disrupt these processes.

Finally, TM4SF1-AS1 has also been shown to be involved in the regulation of the immune response, which is a critical aspect of both physical health and the fight against cancer. The high level of expression of TM4SF1-AS1 has been observed in a variety of immune cells, including T cells and natural killer cells, and has been shown to play a role in regulating the activity of these cells. Additionally, TM4SF1-AS1 has been shown to interact with immune checkpoints, such as the PD-1/TIM-3 interface, which suggests that it may be a good candidate for targeting drugs that are designed to disrupt

Protein Name: TM4SF1 Antisense RNA 1

The "TM4SF1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TM4SF1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets